Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 19/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 19/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | PLD2 | O14939 | 1/20 | 0.76 |
| ▸ | KDM1A | O60341 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | C5 | P01031 | 1/20 | 0.76 |
| ▸ | FYN | P06241 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836618 | 0.92 | NR5A2 (0.85) | NR5A2ESR1ESR2MEN1ALDH1A1 | |
| SCHEMBL18326522 | 0.92 | NR5A2 (0.85) | NR5A2ESR1ESR2MEN1ALDH1A1 | |
| SCHEMBL18326547 | 0.88 | NR5A2 (0.79) | NR5A2ESR1ESR2MEN1ALDH1A1 | |
| SCHEMBL7768189 | 0.88 | NR5A2 (0.78) | NR5A2ESR1ESR2MEN1ALDH1A1 | |
| Raloxifene SCHEMBL29362592 | 0.87 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL3162158 | 0.87 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 0.87 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| SCHEMBL5821250 | 0.87 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL6144 | 0.87 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL16012651 | 0.86 | ESR1 (0.94) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658269-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2025-12-10 | — | — | EP | claimed |
| WO-2024160746-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-08-08 | — | — | WO | claimed |
| EP-4658269-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024160746-A1 | COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-08-08 | — | — | WO | disclosed |
| US-20020173645-A1 | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride | LUKE WAYNE DOUGLAS (US) | 2002-11-21 | — | — | US | disclosed |
| US-6472531-B1 | SINGLE REACTION VESSEL ACYLATION AND DEETHERIFICATION PRODUCTION OF CRYSTALLINE, HIGH PURITY CHEMICAL INTERMEDIATES FOR SUCH AS PHARMACEUTICALS | ELI LILLY AND COMPANY | 2002-10-29 | — | — | US | disclosed |
| US-6399778-B1 | CRYSTALLINE SOLVATE | ELI LILLY AND COMPANY | 2002-06-04 | — | — | US | disclosed |
| US-6008377-A | ACYLATING A N-DISUBSTITUED-PHENYLOXYETHYLAMINE CHLORO OR BROMO SALT WITH A BENZOTHIOPHENE DERIVATIVE IN PRESENCE OF TRIBOROCHLORIDE OR BROMIDE, DEALKYLATING ONE OR MORE PHENOLIC GROUP OF THE PRODUCT WITH ADDITIONAL BOROHALIDE | ELI LILLY AND COMPANY (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1996009045-A1 | ANTIESTROGENIC BENZOTHIOPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173645-A1 | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride | HTR3B, HTR3C, HTR2B | NR5A2 779/4885ESR1 4320/4885ESR2 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.